More on TOVX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+96.9% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (8/12/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Theriva Biologics (NY:TOVX)
Delayed: 0.21 --0 (-0%)
Prev. Close $0.21  
Open$0.21 
52 Wk High$ 
52 Wk Low$ 
Day High$0.21 
Day Low$0.20 
P/E N/A  
EPS$ 
Volume251,503 


Jul 7, 2026 08:11 AM Form 8-K Theriva Biologics, Inc. For: Jul 07
Jul 7, 2026 08:01 AM Theriva Biologics cleared to begin VIRAGE2 pancreatic cancer trial
Jul 7, 2026 08:00 AM Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients
Jun 29, 2026 05:28 PM Form DEF 14A Theriva Biologics, Inc. For: Aug 03
Jun 29, 2026 05:25 PM Form ARS Theriva Biologics, Inc. For: Dec 31
Jun 18, 2026 05:51 PM Form PRE 14A Theriva Biologics, Inc. For: Jun 18
Jun 11, 2026 08:10 AM Form 8-K Theriva Biologics, Inc. For: Jun 11
Jun 11, 2026 08:01 AM Theriva Biologics publishes VCN-01 head and neck cancer trial results
Jun 11, 2026 08:00 AM Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
Jun 5, 2026 04:06 PM Form 8-K Theriva Biologics, Inc. For: Jun 05
View All Articles

Entities mentioned with TOVX

View All Entities